Health Care/Hospital

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100...

2024-04-10 08:40 1554

Neoss Integrate Australia 2024 - Integrate. Educate. Celebrate

QUEENSLAND, Australia, April 9, 2024 /PRNewswire/ -- This summer, Neoss Australia &New Zealand are celebrating 20 years of Intelligent Simplicity and invites the dental community to join us for an exceptional scientific program with over 21 speakers across two days. Taking place on the Gold Coas...

2024-04-09 23:24 1285

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-09 20:00 1179

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial fibrillation, a...

2024-04-09 18:15 1198

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent  * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...

2024-04-09 17:52 1449

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...

2024-04-09 14:00 1314

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...

2024-04-09 09:18 1343

Yunkang Group participated in S&P Global CSA for the first time Ranks above 89% of participating global peers

HONG KONG, April 9, 2024 /PRNewswire/ -- Yunkang Group Limited  ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its score in the "S&P Global Corporate Sustainability Assessment" ("S&P Global CSA"). The Group was invited to partic...

2024-04-09 07:33 3158

TraceLink Named a Leader in IDC MarketScape: Worldwide Multi-Enterprise Supply Chain Commerce Network Vendor Assessment

BOSTON, April 9, 2024 /PRNewswire/ -- TraceLink Inc. has been named a leader in the IDC MarketScape: Worldwide Multi-Enterprise Supply Chain Commerce Network 2023 Vendor Assessment (doc #US49948423,December 2023). We believe this recognition underscores TraceLink's transformative role in orchestr...

2024-04-09 01:00 1271

The first press conference with cats was held in Colombia

* To present the first Casa de Adopción de Amores Imposibles [House of Adoption of Impossible Loves] inColombia, as part of its Adopt Your Allergies campaign, Sanofi held the country's first press conference with cats, giving journalists and content creators the opportunity to meet with the fel...

2024-04-08 22:27 1328

Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"

* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...

2024-04-08 20:00 1571

Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort

-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- -- Preliminary Phase I data in target older adult population is on track for H2-2024 -- SHANGHAI, ...

2024-04-08 17:19 1305

Allianz Partners teams up with Foodbank Australia to improve international students' well being

The partnership will feed over 3,300 international students across three states BRISBANE, Australia, April 8, 2024 /PRNewswire/ -- Allianz Partners has partnered with Foodbank Australia to help alleviate the burden of financial hardship and food insecurit...

2024-04-08 13:24 7982

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK...

2024-04-08 08:47 1314

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2024-04-08 08:00 1707

IMPACT IN ACTION: Cure Brain Cancer Foundation Launches Inaugural 5-Year Guardian Trust Early Career Fellowship valued at $575,000

SYDNEY, April 8, 2024 /PRNewswire/ -- In a historic first, Cure Brain Cancer Foundation proudly unveiled the launch of its groundbreaking 5-Year Guardian Trust Early Career Fellowship, valued at$575,000. The Guardian Trust Early Career Fellowship represents a bold commitment to fostering a new g...

2024-04-08 07:00 1185

Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...

2024-04-06 08:30 3060

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

PARIS, April 6, 2024 /PRNewswire/ -- At the Gamers Assembly in Poitiers, France , Optic 2000 & AUSTRALIEGAD set the best video game players an ambitious challenge: to take on a blind player, equipped with an innovative device, in one of the most legendary games. It was an inspiring experience, des...

2024-04-06 00:35 2544

HSA approves new asthma indication for GSK's Trelegy Ellipta, the first once-daily single inhaler triple therapy approved for use in the treatment of both asthma and COPD in Singapore

SINGAPORE, April 5, 2024 /PRNewswire/ -- GSK Singapore announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 yea...

2024-04-05 16:00 2702

LBB Specialties Announces Principal Partnership with VIZOR

NORWALK, Conn., April 4, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution in North America, announces a new partnership with VIZOR®, a global leader in Zinc Oxide Powders and Dispersions. LBB Specialties will be VIZOR's exclusive channel part...

2024-04-04 21:01 1811
12345678 ... 553